Trevena CEO to Present at the Canaccord Genuity 34th Annual Growth Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical-stage biopharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 1:30 p.m. EDT at The InterContinental in Boston.
To access a live audio webcast of the presentation, please visit the “Investors” section at www.trevenainc.com. The webcast will be archived for two weeks.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe acute pain intravenously, and TRV734 to treat moderate-to-severe acute and chronic pain orally. Trevena also is advancing additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.
Director of investor relations
President and chief executive officer
Source: Trevena, Inc.
Released August 7, 2014